Gavilimomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD147 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]
It was originally developed by Abgenix,[1] which was later acquired by Amgen.
References
- ^ a b "Gavilimomab". Adis Insight. Springer Nature Switzerland AG.
- ^ Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, et al. (March 2007). "A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease". Blood. 109 (6): 2657–62. doi:10.1182/blood-2006-08-013995. PMID 17110457.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |